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background: In patients with systolic heart failure (HF) but without atrial fibrillation (AF), the WARCEF trial found that warfarin reduced stroke risk 
but increased bleeding compared with aspirin. For this analysis, we sought to determine whether existing bleeding risk scores could be applied to 
this patient population.
Methods: HAS-BLED and ORBI risk scores were calculated for 1,142 patients randomized to warfarin and 1,163 patients randomized to aspirin 
in the WARCEF trial. Major bleeding was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage, or 
bleeding causing a decline in hemoglobin of >2 g/dL or requiring hospitalization, surgical intervention, or transfusion of ≥2 units PRBC. Proportional 
hazards models were used to test whether each score predicted bleeding risk, and comparison of different risk scores was performed using Harell’s 
c-index.
results: HAS-BLED and ORBI risk scores both predicted bleeding risk for participants in the warfarin arm (p=0.03 and p<0.01 for trend, 
respectively). For participants in the aspirin arm, HAS-BLED, but not ORBI, was predictive of major bleeding. The ORBI risk score had superior 
discrimination compared to HAS-BLED for participants receiving warfarin (Harell’s c-index 0.64 vs 0.56; p=0.02).
conclusions: Our results suggest bleeding risk scores such as ORBI can guide patient selection for future trials testing anti-coagulation strategies 
in individuals with systolic HF but without AF.
 
